Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Byetta Pancreatic Cancer Claims Currently Under Investigation

(Medical-NewsWire.com, June 28, 2013 ) New York, NY – The attorneys working with ClassAction.org are currently investigating potential lawsuits on behalf of Byetta users who were diagnosed with pancreatic cancer. It has been alleged that the drug, used to lower blood sugar levels in patients with Type 2 diabetes, can increase a patient’s risk of developing pancreatic cancer. If you or a loved one has used Byetta and has been diagnosed with pancreatic cancer, you may be able to take legal action against the makers of the drug to recover financial compensation for medical bills and other losses. Free online consultations are now being offered at ClassAction.org, a website dedicated to keeping patients informed about product alerts, recalls and emerging litigation. Please visit http://www.classaction.org/byetta.html and fill out the form on the right for more information.

A number of lawsuits have been filed on behalf of Byetta users alleging that Amylin Pharmaceuticals and Eli Lilly and Co. knew that Byetta can cause life-threatening pancreatic cancer and failed to adequately warn both patients and doctors about this risk. According to one lawsuit, the makers of Byetta did not even mention “pancreatic cancer” on the drug’s product insert. It has also been alleged that doctors were not warned or advised to institute monitoring procedures to indicate initial signs of changes within the pancreas. Even if the manufacturers had provided adequate warnings, the benefits of Byetta do not outweigh its risks, especially with the availability of other diabetes drugs, the suits allege.

In March 2013, the FDA announced that it would be “evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis. . .and pre-cancerous cell changes” in Type 2 diabetes patients treated with drugs in the incretin mimetic class, which includes both Byetta and Januvia. The agency has not reached any new conclusions about the safety risks with these drugs, but issued the communication to inform the public and medical community that they would “obtain and evaluate this new information.”
If you or a loved one has been diagnosed with pancreatic cancer after using Byetta, you may have legal recourse to collect financial compensation for your losses. For more information, please visit ClassAction.org.

About Class Action.org

Class Action.org is dedicated to protecting consumers and investors in class actions and complex litigation throughout the United States. Class Action.org keeps consumers informed about product alerts, recalls, and emerging litigation and helps them take action against the manufacturers of defective products, drugs, and medical devices. Information about consumer fraud issues and environmental hazards is also available on the site. Visit http://www.classaction.org today for a no cost, no obligation case evaluation and information about your consumer rights.

ClassAction.org

Hannah Armstrong

8004491970

pressrelease@lawyercentral.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC